Jeff Elton sits down with Dr. Robert Miller, Chief Medical and Science Officer at CancerLinQ, to unpack the integration of real-world data and AI in oncology care. Dr. Miller shares his journey from community practice to shaping CancerLinQ, revealing insights into the network's growth and its pivotal role in improving patient care. The episode delves into the transformation of quality measures, the burgeoning role of electronic health records, and the automation of data to enhance the quality and reach of oncological care. As CancerLinQ evolves, discover its expanding capabilities, the drive towards patient-centric care, and the influence on CancerLinQ's partnerships, particularly with ASCO. This is a must-listen for professionals seeking to understand the landscape of data-driven healthcare improvements. Tune in to explore the trajectory of oncology practice transformation with two industry leaders at the helm.

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

Jeff Elton, CEO of ConcertAI, and George Sledge, CMO of Caris Life Sciences, embark on an insightful journey through the advancements in oncology. They explore the transformative power of molecular diagnostic testing and how comprehensive data sets are revolutionizing personalized medicine. Delving into topics like the rise of liquid biopsies, which enable non-invasive, next-gen sequencing, they highlight the potential for easier and safer tumor monitoring. Challenges like the limitations of analyzing small populations are addressed, emphasizing the value of large-scale, actionable databases in understanding diseases like breast cancer. They also discuss the future of molecular diagnostics in streamlining cancer prevention trials and the need to look beyond "gateway mutations" for a deeper understanding of dynamic cancer evolution. A key theme is the collaborative synergy between ConcertAI and Caris Life Sciences, emphasizing the goal of producing high-quality, meaningful data that can shape the future of oncological research and care.

Interested in learning more about ConcertAI and Caris Life Science's joint offering? Download our factsheet today!

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai

In this engaging episode, David Spetzler, President of Caris Life Sciences, and Jeff Elton, CEO of ConcertAI, discuss the transformative power of combining clinical insights and advanced AI technologies to revolutionize patient care in oncology. Highlighting their collaborative efforts, they emphasize the critical role of comprehensive data analysis, from leveraging longitudinal clinical records to employing next-generation sequencing for personalized treatment strategies. The conversation underscores a shared commitment to advancing medical science by accelerating the development and validation of new therapies, ultimately aiming to enhance patient outcomes through precision medicine. Through this partnership, they envision a future where diagnostics and targeted treatment strategies significantly extend human life years, demonstrating the profound impact of integrating cutting-edge technology and collaborative innovation in healthcare.

Watch the live video interview here:
https://vimeo.com/816357933/ab745bd0a1?share=copy

Website
www.ConcertAI.com

LinkedIn
www.linkedin.com/company/concertai/

Twitter
www.twitter.com/concertai